Insight

Jul 27, 2024, 14:49

Identification of Resistance Biomarkers to HER2 Inhibitors

Iván González, Medical Oncologist at Comprehensive Oncology Center, Hospital Angeles Puebla, shared a post on X about a paper titled “Depicting Biomarkers for HER2-Inhibitor Resistance: Implication for Therapy in HER2-Positive Breast Cancer” published in MDPI.

Authors: Alvan Cai, Yuan Chen, Lily S. Wang, John K. Cusick and Yihui Shi.

“Identification of Resistance Biomarkers to HER2 Inhibitors: Advances and Challenges in HER2+ Breast Cancer.

Therapeutic advances: HER2 inhibitors have significantly improved the treatment of HER2+ breast cancer.
Persistent challenge: Resistance to these drugs remains a critical issue.
Key biomarkers identified: Mutations in the ERBB2 gene, activation of alternative signaling pathways, expression of estrogen receptors, and alterations in regulatory protein levels have been found.
New explorations: More effective regimens and promising combination therapies are being investigated.

This review highlights current HER2-targeted therapies, analyzes predictive biomarkers of drug resistance, and presents emerging therapies, especially combination treatments, aimed at overcoming resistance in the context of HER2+ breast cancer.”

Identification of Resistance Biomarkers to HER2 Inhibitors

Source: Iván González/X

Alvan Cai cancer HER2 positive breast cancer HER2-Inhibitor Hospital Ángeles Puebla Iván González John K. Cusick Key biomarkers Lily S. Wang MDPI OncoDaily Oncology Therapeutic advances Yihui Shi Yuan Chen

Immunotherapy for Melanoma: Types, Success Rate, Side Effects & More

Tom Green and Testicular Cancer: How He Went Against, How He Survived, and More

Steven O'Day: At the Forefront of Immunotherapy

Dennis Slamon was honored with the 2024 Szent-Györgyi Prize for Progress in Cancer Research

Pfizer is partnering with Patrick Dempsey in support of the American Cancer Society initiative 'Change the Odds'

Special Coverage